1. Clinical Overview of Cartalax
Molecule: Cartalax (Ala-Glu-Asp) is a synthetic tripeptide bioregulator derived from bovine cartilage tissue, developed by the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Prof. Vladimir Khavinson. It is a tissue-specific peptide that exerts targeted regulatory activity in chondrocytes, extracellular matrix (ECM) tissue, and articular cartilage.
Key Properties
- Tissue-specific chondroprotective bioregulator
- Promotes chondrocyte proliferation and ECM anabolism
- Epigenetic modulator — activates cartilage-specific gene expression
- Anti-inflammatory activity within synovial and pericartilaginous tissue
- Inhibits catabolic matrix metalloproteinase (MMP) activity
- Supports collagen type II and proteoglycan synthesis
- Well-tolerated with favorable short- and long-term safety profile
Primary Roles
- Cartilage preservation and regenerative support
- Chondrocyte viability and proliferation
- Joint pain reduction and functional restoration
- Post-surgical and post-injury articular recovery
- Anti-aging connective tissue maintenance
- Intervertebral disc and spinal cartilage support
2. Mechanisms of Action
2.1 Epigenetic Regulation of Chondrocyte Gene Expression
Cartalax operates as a peptide bioregulator through direct interaction with chromatin, specifically influencing histone acetylation and DNA methylation states to restore or enhance expression of cartilage-specific genes. Research from the Khavinson laboratory demonstrates that short peptide bioregulators bind directly to DNA promoter sequences, activating transcription of target tissue genes — including those encoding COL2A1 (collagen type II), aggrecan, and SOX9.
Clinical significance: Unlike NSAIDs or corticosteroids that suppress symptoms without addressing tissue biology, Cartalax acts upstream at the gene regulation level to promote regenerative chondrocyte function rather than simply masking inflammation.
2.2 Chondrocyte Proliferation & Anabolic Matrix Synthesis
Cartalax directly stimulates chondrocyte mitotic activity and biosynthetic output, leading to:
- Increased production of collagen type II — the primary structural collagen of articular cartilage
- Enhanced synthesis of proteoglycans (aggrecan, versican) that maintain cartilage hydration and compressive load tolerance
- Upregulation of glycosaminoglycans (GAGs), including chondroitin sulfate and keratan sulfate
- Improved chondrocyte density within the cartilage matrix
2.3 Anti-Inflammatory & MMP Inhibition
Cartalax modulates the inflammatory microenvironment within synovial and periarticular tissue by:
- Downregulating pro-inflammatory cytokines: IL-1β, IL-6, TNF-α
- Inhibiting matrix metalloproteinases MMP-1, MMP-3, and MMP-13 — key mediators of cartilage degradation in osteoarthritis
- Reducing NF-κB pathway activation in inflamed synoviocytes
- Shifting macrophage polarization toward the anti-inflammatory M2 phenotype in periarticular tissue
Clinical significance: By simultaneously stimulating anabolic matrix production and suppressing catabolic enzyme activity, Cartalax creates a favorable anabolic-to-catabolic ratio in joint tissue — the critical determinant of cartilage net balance over time.
2.4 Chondrocyte Apoptosis Suppression
In degenerative joint conditions, chondrocyte apoptosis is a primary driver of irreversible cartilage loss. Cartalax has demonstrated antiapoptotic activity via:
- Upregulation of Bcl-2 (anti-apoptotic) and suppression of Bax (pro-apoptotic) expression
- Reduction of caspase-3 activation under inflammatory stress conditions
- Protection of mitochondrial membrane integrity in chondrocytes exposed to oxidative stress
2.5 Subchondral Bone & Synovial Membrane Influence
Emerging evidence suggests Cartalax also exerts regulatory influence on adjacent joint structures, including normalization of subchondral bone remodeling dynamics and reduction of synovial hypertrophy — both of which contribute to improved biomechanical joint function and reduced pain load in osteoarthritic joints.
3. Evidence-Based Clinical Applications
3.1 Osteoarthritis (OA) — Primary Indication
Cartalax is most extensively studied and applied in osteoarthritis management, with clinical and preclinical data supporting:
- Reduction in joint pain scores (VAS) across knee, hip, and small joint OA
- Improvements in functional mobility and range of motion
- Slowing of radiographic cartilage space narrowing over multi-year follow-up in Russian longitudinal studies
- Reduction in NSAID and analgesic reliance in actively treated cohorts
Clinical note: Cartalax is often considered a foundational peptide for integrative OA protocols, frequently stacked with BPC-157, TB-500, or hyaluronic acid to address multiple pathophysiological domains simultaneously.
3.2 Post-Surgical Joint Recovery
Following arthroscopic procedures, meniscal repair, ACL reconstruction, or joint replacement, Cartalax supports accelerated recovery through:
- Enhanced chondrocyte repopulation at resurfacing sites
- Reduced post-operative synovial inflammation
- Promotion of collagen scaffold formation in healing tissue
- Shorter time to functional weight-bearing and mobility restoration
3.3 Athletic & Sports Medicine Applications
In high-demand athletic populations, repetitive joint loading and microtrauma create a chronic low-grade catabolic environment in cartilage. Cartalax is applied for:
- Preventive cartilage maintenance in high-impact sport athletes
- Acute injury recovery (ligament, tendon-adjacent cartilage damage)
- Return-to-play acceleration following joint injury
- Off-season joint restoration cycling
3.4 Intervertebral Disc & Spinal Cartilage Degeneration
The nucleus pulposus of intervertebral discs shares key biological characteristics with articular cartilage, including reliance on proteoglycan-rich ECM for hydration and load distribution. Cartalax shows potential applicability in:
- Discogenic back pain and early disc degeneration
- Facet joint arthrosis
- Cervical and lumbar spondylosis management
3.5 Longevity & Age-Related Connective Tissue Maintenance
As part of comprehensive longevity peptide protocols, Cartalax addresses the progressive age-related decline in chondrocyte biosynthetic capacity. Regular cycling in patients aged 45+ may support:
- Preservation of articular cartilage thickness
- Maintenance of joint fluid viscosity and lubrication
- Reduced risk of advanced OA progression
- Integration with systemic peptide anti-aging protocols (Epitalon, Thymalin, Vilon)
3.6 Rheumatoid & Inflammatory Arthropathies (Adjunctive)
While not a primary disease-modifying agent in autoimmune arthritis, Cartalax may serve an adjunctive role in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis by:
- Protecting residual cartilage from inflammatory destruction
- Supporting joint tissue repair during remission phases
- Complementing DMARDs and biologics without known pharmacological interference
Note: Use in active autoimmune flares should be approached conservatively and only under direct rheumatological supervision.
4. Administration & Dosing Protocols
Cartalax is compounded and administered primarily via subcutaneous injection and oral capsules. Injectable administration remains the best-studied route based on the original Khavinson bioregulator research. Oral formulations offer a practical maintenance option with reduced but clinically meaningful bioavailability.
4.1 Subcutaneous Injection (Primary / Most Studied Route)
Standard Dose: 5–10 mg per injection session
Frequency: Daily or every other day × 10–20 sessions per cycle
Injection site: Subcutaneous — abdomen, lateral thigh, or upper arm
Cycle duration: 10–20 days for acute/therapeutic protocols; 10-day cycles repeated 2–3× per year for maintenance
Reconstitution: Lyophilized powder reconstituted in bacteriostatic water or sterile saline; use within 28 days when refrigerated
4.2 Oral Capsule Administration
Dose: 10–20 mg per day, taken with or without food
Timing: Morning dosing preferred; may split into two doses (AM/PM) at higher end of range
Cycle duration: 30–60 days per cycle; repeat 2–3× per year
Note: Oral bioavailability is lower than subcutaneous; dosing is adjusted proportionally. Suitable for maintenance, prevention, and patients who prefer non-injectable routes.
4.3 Condition-Specific Dosing Protocols
Osteoarthritis (Mild to Moderate)
- SQ: 5 mg every other day × 10 injections per cycle; 2–3 cycles/year
- Oral: 10 mg daily × 30–45 days; 2–3 cycles/year
- Consider concurrent oral supplementation with collagen type II, glucosamine, and chondroitin
Osteoarthritis (Moderate to Severe)
- SQ: 10 mg daily × 10–20 sessions; repeat every 3–4 months
- May be stacked with BPC-157, TB-500, or platelet-rich plasma (PRP) injections for synergistic tissue repair
- Consider combination with intra-articular hyaluronic acid for joint lubrication support
Post-Surgical Recovery
- SQ: 5–10 mg daily beginning 2–4 weeks post-operatively (after wound healing is established)
- Duration: 10–20 sessions; may repeat once 6–8 weeks later
- Often stacked with BPC-157 for synergistic collagen remodeling effects
Athletic Maintenance & Prevention
- Oral: 10 mg daily × 30 days; 2× per year (off-season or planned rest periods)
- SQ option: 5 mg every other day × 10 sessions annually
Longevity / Anti-Aging Protocol
- Oral: 10 mg daily × 30 days; 1–2× per year as part of broader peptide bioregulator cycling
- Often integrated with Epitalon, Thymalin, and Vilon in comprehensive tissue-targeted protocols
4.4 Stacking Considerations
Cartalax is commonly combined with complementary peptides and agents for enhanced clinical effect:
- BPC-157 — synergistic collagen synthesis and tendon/ligament repair; excellent pairing for post-surgical and sports injury protocols
- TB-500 (Thymosin Beta-4) — promotes actin polymerization, tissue remodeling, and anti-inflammatory signaling
- GHK-Cu — copper peptide with potent anti-inflammatory and ECM remodeling properties; useful in systemic connective tissue programs
- Epitalon — telomerase activation and anti-aging; commonly combined in comprehensive Khavinson longevity protocols
- PRP / PRF — growth factor-rich biologics that complement Cartalax's chondroprotective effects; synergistic intra-articular or periarticular use
- Hyaluronic acid (oral or IA) — joint lubrication and synovial fluid viscosity support
4.5 Duration & Cycling
- Acute therapeutic: 10–20 day injectable course; repeat as needed based on clinical response
- Maintenance cycling: 2–3 courses per year (injectable or oral)
- Long-term monitoring: Clinical reassessment at 6-month intervals; imaging (X-ray, MRI) annually in advanced OA cases
5. Clinical Decision Trees
Decision Tree 1 — Is Cartalax Appropriate?
Joint pain with confirmed or suspected cartilage involvement? → Yes
Osteoarthritis (any grade)? → Strong Yes
Post-surgical joint recovery? → Yes
Athletic joint maintenance or injury recovery? → Yes
Age-related connective tissue decline (45+)? → Yes
Intervertebral disc or spinal cartilage involvement? → Consider
Active autoimmune arthritis (RA, PsA)? → Use adjunctively / consult rheumatology
Active malignancy? → Contraindicated
Decision Tree 2 — Route & Dose Selection
Active OA / acute pain → SQ 10 mg daily × 10–20 sessions
Mild OA / early degeneration → SQ 5 mg EOD × 10 sessions · or Oral 10 mg/day × 30 days
Post-surgical recovery → SQ 5–10 mg daily × 10–20 sessions
Athletic maintenance → Oral 10 mg/day × 30 days · 2× per year
Longevity / anti-aging → Oral 10 mg/day × 30 days · 1–2× per year
Patient prefers non-injectable → Oral 10–20 mg/day × 30–60 days
Decision Tree 3 — Stacking Strategy
OA + systemic inflammation → Add BPC-157 + GHK-Cu
Post-surgical / soft tissue involvement → Add BPC-157 + TB-500
Athletic injury recovery → Add TB-500 + BPC-157
Longevity program → Add Epitalon + Thymalin
Intra-articular support needed → Add PRP/PRF ± hyaluronic acid
6. Safety, Contraindications & Monitoring
6.1 Contraindications
- Pregnancy or breastfeeding
- Active malignancy or history of cartilage/connective tissue cancer (theoretical proliferative concern)
- Hypersensitivity to any peptide component or bovine-derived products
- Active systemic infection (defer treatment until resolved)
- Severe hepatic or renal impairment (limited data; use with caution)
6.2 Potential Side Effects
Cartalax has a favorable tolerability profile in published literature. Side effects are generally mild and transient:
- Injection site reactions — mild erythema, transient tenderness, or induration (most common; typically resolves within 24–48 hours)
- Transient fatigue or mild flu-like sensation in first 1–2 days of a new cycle (uncommon)
- GI discomfort with oral formulations — rare; typically resolves with food co-administration
- Theoretical concern for promoting growth in pre-existing undetected neoplastic tissue — screen appropriately before initiating
- No known drug-drug interactions reported in available literature; exercise clinical judgment when combining with DMARDs or immunosuppressants
6.3 Monitoring Recommendations
- Baseline joint assessment: VAS pain score, functional mobility testing, imaging (X-ray ± MRI) for OA staging
- Reassessment at 4–6 weeks during initial treatment cycle and at cycle completion
- Annual imaging in patients with moderate-to-severe OA to assess cartilage space
- Monitor for injection site reactions; rotate sites systematically
- Baseline inflammatory markers (CRP, ESR) in patients with inflammatory arthropathy; repeat at 3-month intervals
- Screen for active infection or malignancy prior to initiating any peptide bioregulator protocol
- Periodic review of concomitant medications, particularly anticoagulants (injection-site consideration) and immunomodulators
Legal Disclaimer
The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
Cartalax (Ala-Glu-Asp), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, subcutaneous, topical, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.
Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.
Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.
By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.
Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.
References — Cartalax Clinical Reference Guide
Peptide Bioregulator Research — Khavinson Laboratory
1. Khavinson, V. Kh., & Morozov, V. G. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters, 24(3–4), 233–240 (2003).
2. Khavinson, V. Kh., et al. Short peptide bioregulators for the correction of age-related changes in tissues. Bulletin of Experimental Biology and Medicine, 151(1), 115–119 (2011).
3. Khavinson, V. Kh., et al. Peptide regulation of gene expression: a systematic review. Molecules, 28(4), 1549 (2023).
Chondroprotection & Cartilage Matrix Biology
4. Loeser, R. F., et al. Osteoarthritis: a disease of the joint as an organ. Arthritis & Rheumatism, 64(6), 1697–1707 (2012).
5. Buckwalter, J. A., & Mankin, H. J. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instructional Course Lectures, 47, 487–504 (1998).
6. Goldring, M. B., & Goldring, S. R. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Annals of the New York Academy of Sciences, 1192, 230–237 (2010).
Epigenetic Mechanisms of Peptide Bioregulation
7. Vanyushin, B. F., & Khavinson, V. Kh. Short biologically active peptides as epigenetic modulators of gene activity. Biochemistry (Moscow), 72(11), 1571–1577 (2007).
8. Khavinson, V. Kh., et al. Peptide epigenetic regulators: novel tools for tissue regeneration and longevity. Frontiers in Genetics, 11, 612 (2020).
Inflammation & MMP Activity in Osteoarthritis
9. Bondeson, J., et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, cartilage degradation, and other destructive factors in osteoarthritis. Arthritis Research & Therapy, 12(1), R57 (2010).
10. Troeberg, L., & Nagase, H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochimica et Biophysica Acta, 1824(1), 133–145 (2012).
Chondrocyte Apoptosis & Cell Survival
11. Hwang, H. S., & Kim, H. A. Chondrocyte apoptosis in the pathogenesis of osteoarthritis. International Journal of Molecular Sciences, 16(11), 26035–26054 (2015).
12. Mobasheri, A., et al. The role of metabolism in the pathogenesis of osteoarthritis. Nature Reviews Rheumatology, 13(5), 302–311 (2017).
Bioregulator Peptide Clinical Outcomes & Longevity
13. Anisimov, V. N., et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202 (2003).
14. Kuznik, B. I., et al. Bioregulatory peptides: prospects for use in gerontology and regenerative medicine. Advances in Gerontology, 25(2), 200–209 (2012).
Combination Regenerative Approaches
15. Siebert, C. H., et al. Regenerative approaches to cartilage repair: current status and future directions. Knee Surgery, Sports Traumatology, Arthroscopy, 17(11), 1376–1382 (2009).
16. Kon, E., et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology. Arthroscopy, 27(11), 1490–1501 (2011).